Hainan He Rui Pharmaceutical Co. Ltd.

To evaluate the pharmacokinetic characteristics of different doses of landiolol hydrochloride for injection in healthy Chinese adult subjects.

Primary objective: To evaluate the effectiveness of landiolol hydrochloride injection in the treatment of tachycardia-induced arrhythmias during general anesthesia surgery. Secondary objective: To evaluate the safety of landiolol hydrochloride injection in the treatment of tachycardia-induced arrhythmias during general anesthesia surgery.

To investigate the pharmacokinetic characteristics of a single oral administration of Iguratimod tablets (test preparation, specification: 25 mg) produced by Hainan Herui Pharmaceutical Co., Ltd. under fasting and postprandial conditions in healthy subjects and a single oral administration of Iguratimod tablets (reference preparation, trade name: Edexin®, specification: 25 mg) certified by Hainan Xiansheng Pharmaceutical Co., Ltd. under the same conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.